Study design (if review, criteria of inclusion for studies)
Open label, parallel group, randomised controlled trial
Participants
Children and young people aged 6 to 18 years with CF at 13 paediatric CF treatment centres in the UK.
Interventions
Participants were randomised equally to either receive oral rosuvastatin (10 mg once daily) or no intervention (control) throughout clinically indicated treatment with intravenous tobramycin.
Outcome measures
The primary outcome was the difference between the groups in mean fold-change in urinary Kidney Injury Molecule-1 (KIM-1).
Main results
Fifty (rosuvastatin n = 23, control n = 27) participants were recruited between May 2015 and January 2017. Primary outcome data was available for 88% (rosuvastatin n = 20, control n = 24). The estimated mean treatment difference in the geometric mean-fold change of normalised KIM-1 was 1.08 (95% CI 0.87-1.35, p = 0.48). In total there were 12 adverse reactions, all mild, reported by five participants randomised to rosuvastatin, and one serious adverse event in each group. Whilst no protective effect of rosuvastatin was seen, there was a lower than expected level of nephrotoxicity in the cohort. Therefore, we can neither confirm nor refute the hypothesis that rosuvastatin protects against aminoglycoside nephrotoxicity.
Authors' conclusions
Authors can neither confirm nor refute the hypothesis that rosuvastatin protects against aminoglycoside nephrotoxicity.
Related topics
Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis
Antibiotic treatment of early pseudomonas aeruginosa
Antibiotics for pulmonary exacerbations
Inhaled antibiotics in cystic fibrosis
Prophylactic use of oral antistaphylococcal antibiotic
Scheduled antibiotics every 3-4 months / symptom-based treatment